

# **Pneumonia Therapeutics Market Analysis By Product (Drugs, Branded, Quinolones, Aminopenicillins, Macrolides, B-lactamase Inhibitors, Cephalosporins, Tetracyclines, Glycopeptides, Generics, Vaccines, Oxygen Therapy) And Segment Forecasts, 2014 - 2025**

<https://marketpublishers.com/r/P91FB104918EN.html>

Date: July 2017

Pages: 102

Price: US\$ 5,950.00 (Single User License)

ID: P91FB104918EN

## **Abstracts**

The global pneumonia therapeutics market is expected to reach USD 22.9 billion by 2025, according to a new report by Grand View Research, Inc. This market is anticipated to grow at an unprecedented rate owing to the increasing prevalence of pneumococcal disease globally. The increasing demand for pneumonia therapeutics is a result of unmet clinical needs in emerging as well as developed regions. Increasing focus of healthcare organizations on raising awareness and issuing guidelines for efficient management of pneumococcal disease is predicted to broaden the scope for growth over the coming years. For instance, Infectious Diseases Society of America/American Thoracic Society has issued guidelines on the management of community-acquired pneumonia. According to a white paper released by American Academy of Family Physicians, adherence to these guidelines has resulted in positive patient outcomes during the treatment of community-acquired bacterial pneumonia in patients.

Moreover, growing R&D activities in life sciences are anticipated to create positive impact on the market over the coming years. Consequentially, increase in number of products, currently being reviewed under clinical trials, is anticipated to fuel the overall growth. In the present scenario, there are 12 drugs under investigation in phase III trials, 4 drugs under phase II, and 3 drugs under phase I trial. The aforementioned factors exemplify the consistent efforts being made by the market players. For instance, Omadacycline, a tetracycline under phase III clinical trial, developed by Paratek Pharmaceuticals is being investigated for use in the treatment of ventilator-associated

and community-acquired bacterial pneumonia.

#### Further Key Findings From the Report Suggest:

Vaccines accounted for the largest share in the product segment in 2016. This can be attributed to their high efficacy and growing inclination of patients toward preventive measures

They are also expected to grow at a lucrative rate owing to the recommendation by WHO for their inclusion in national immunization programs

Drugs are expected to witness moderate growth rate throughout the forecast period. This is believed to be a result of the infiltration of generic drugs that are more cost-efficient.

North America accounted for a substantial share in the market owing to an increasing number of supportive government initiatives and high awareness levels amongst the end-users

Asia Pacific is expected to witness exponential CAGR during the forecast period owing to its high disease burden and continual infrastructural upgradation of research & manufacturing facilities in the region

High competition has been observed in the market, where major players adopt strategies such as new product development, collaborations, and strategic agreements to gain market share

## Contents

### **CHAPTER 1 RESEARCH METHODOLOGY & SCOPE**

- 1.1 Region-wise Market Calculation
  - 1.1.1 Region-wise market: Base estimates
  - 1.1.2 Global market: CAGR calculation
- 1.2 Region-based Segment Share Calculation
- 1.3 List of Secondary Sources

### **CHAPTER 2 EXECUTIVE SUMMARY**

- 2.1 Region Wise Market Calculation

### **CHAPTER 3 PNEUMONIA THERAPEUTICS MARKET VARIABLES, TRENDS & SCOPE**

- 3.1 Market Segmentation & Scope
- 3.2 Market Driver Analysis
- 3.3 Market Restraint Analysis
- 3.4 Penetration & Growth Prospect Mapping
- 3.5 Pneumonia Therapeutics Market - SWOT Analysis, By Factor (Political & legal, economic and technological)
- 3.6 Industry Analysis - Porter's
- 3.7 Product Pipeline Analysis - Pneumonia Therapeutics
- 3.8 Company Market Share, 2016

### **CHAPTER 4 PNEUMONIA THERAPEUTICS MARKET: PRODUCT ESTIMATES & TREND ANALYSIS**

- 4.1 Pneumonia Therapeutics Market: Product Movement Analysis
- 4.2 Drugs
  - 4.2.1 Drugs market estimates and forecasts, 2014 - 2025 (USD Million)
  - 4.2.2 Branded
    - 4.2.2.1 Branded market estimates and forecasts, 2014 - 2025 (USD Million)
    - 4.2.2.2 Quinolones
      - 4.2.2.2.1 Quinolones market estimates and forecasts, 2014 - 2025 (USD Million)
    - 4.2.2.3 Aminopenicillins
      - 4.2.2.3.1 Aminopenicillins creams market estimates and forecasts, 2014 - 2025

(USD Million)

4.2.2.4 Macrolides

4.2.2.4.1 Macrolides market estimates and forecasts, 2014 - 2025 (USD Million)

4.2.2.5 B-lactamase inhibitors

4.2.2.5.1 B-lactamase inhibitors market estimates and forecasts, 2014 - 2025 (USD Million)

4.2.2.6 Cephalosporins

4.2.2.6.1 Cephalosporins market estimates and forecasts, 2014 - 2025 (USD Million)

4.2.2.7 Tetracyclines

4.2.2.7.1 Tetracyclines market estimates and forecasts, 2014 - 2025 (USD Million)

4.2.2.8 Glycopeptide antibiotics

4.2.2.8.1 Glycopeptide antibiotics market estimates and forecasts, 2014 - 2025 (USD Million)

4.2.2.9 Carbapenems

4.2.2.9.1 Carbapenems market estimates and forecasts, 2014 - 2025 (USD Million)

4.2.2.10 Others

4.2.2.10.1 Others market estimates and forecasts, 2014 - 2025 (USD Million)

4.2.3 Generics

4.2.3.1 Generics market estimates and forecasts, 2014 - 2025 (USD Million)

4.2.3.2 Quinolones

4.2.3.2.1 Quinolones market estimates and forecasts, 2014 - 2025 (USD Million)

4.2.3.3 Macrolides

4.2.3.3.1 Macrolides market estimates and forecasts, 2014 - 2025 (USD Million)

4.2.3.4 Others

4.2.3.4.1 Others market estimates and forecasts, 2014 - 2025 (USD Million)

4.3 Vaccines

4.3.1 Vaccines market estimates and forecasts, 2014 - 2025 (USD Million)

4.4 Oxygen Therapy

4.4.1 Oxygen therapy market estimates and forecasts, 2014 - 2025 (USD Million)

## **CHAPTER 5 PNEUMONIA THERAPEUTICS MARKET: REGIONAL ESTIMATES & TREND ANALYSIS, BY PRODUCT**

### 5.1 Pneumonia Therapeutics Market Shares by Region, 2016 & 2025

#### 5.2 North America

5.2.1 North America pneumonia therapeutics market, by product, 2014 - 2025 (USD Million)

5.2.2 U.S.

5.2.2.1 U.S. pneumonia therapeutics market, by product, 2014 - 2025 (USD Million)

5.2.3 Canada

5.2.3.1 Canada pneumonia therapeutics market, by product, 2014 - 2025 (USD Million)

5.3 Europe

5.3.1 Europe pneumonia therapeutics market, by product, 2014 - 2025 (USD Million)

5.3.2 Germany

5.3.2.1 Germany pneumonia therapeutics market, by product, 2014 - 2025 (USD Million)

5.3.3 UK

5.3.3.1 UK pneumonia therapeutics market, by product, 2014 - 2025 (USD Million)

5.4 Asia Pacific

5.4.1 Asia Pacific pneumonia therapeutics market, by product, 2014 - 2025 (USD Million)

5.4.2 Japan

5.4.2.1 Japan pneumonia therapeutics market, by product, 2014 - 2025 (USD Million)

5.4.3 China

5.4.3.1 China pneumonia therapeutics market, by product, 2014 - 2025 (USD Million)

5.4.4 India

5.4.4.1 India pneumonia therapeutics market, by product, 2014 - 2025 (USD Million)

5.5 Latin America

5.5.1 Latin America pneumonia therapeutics market, by product, 2014 - 2025 (USD Million)

5.5.2 Brazil

5.5.2.1 Brazil pneumonia therapeutics market, by product, 2014 - 2025 (USD Million)

5.5.3 Mexico

5.5.3.1 Mexico pneumonia therapeutics market, by product, 2014 - 2025 (USD Million)

5.6 MEA

5.6.1 MEA pneumonia therapeutics market, by product, 2014 - 2025 (USD Million)

5.6.2 South Africa

5.6.2.1 South Africa pneumonia therapeutics market, by product, 2014 - 2025 (USD Million)

## **CHAPTER 6 COMPETITIVE LANDSCAPE**

6.1 Market Participation Categorization

6.2 Company Profiles

6.2.1 Pfizer, Inc.

- 6.2.1.1 Company overview
- 6.2.1.2 Financial Performance
- 6.2.1.3 Product benchmarking
- 6.2.2 Bayer AG
  - 6.2.2.1 Company Overview
  - 6.2.2.2 Financial Performance
  - 6.2.2.3 Product Benchmarking
- 6.2.3 Abbott
  - 6.2.3.1 Company Overview
  - 6.2.3.2 Financial Performance
  - 6.2.3.3 Product Benchmarking
- 6.2.4 Merck & Co., Inc.
  - 6.2.4.1 Company overview
  - 6.2.4.2 Financial Performance
  - 6.2.4.3 Product Benchmarking
- 6.2.5 Novartis AG
  - 6.2.5.1 Company overview
  - 6.2.5.2 Financial performance
  - 6.2.5.3 Product benchmarking
- 6.2.6 GlaxoSmithKline plc
  - 6.2.6.1 Company overview
  - 6.2.6.2 Financial Performance
  - 6.2.6.3 Product benchmarking
- 6.2.7 Allergan
  - 6.2.7.1 Company overview
  - 6.2.7.2 Financial performance
  - 6.2.7.3 Product benchmarking
- 6.2.8 Lupin Pharmaceuticals, Inc.
  - 6.2.8.1 Company Overview
  - 6.2.8.2 Financial Performance
  - 6.2.8.3 Product Benchmarking

## List Of Tables

### LIST OF TABLES

Table 1 Country share estimation

Table 2 Pneumonia Drugs - Patent Expiries

Table 3 Pneumonia Therapeutics - Pipeline Overview

Table 4 North America pneumonia therapeutics market, by product, 2014 - 2025 (USD Million)

Table 5 North America drugs market, by type, 2014 - 2025 (USD Million)

Table 6 North America branded drugs market, by type, 2014 - 2025 (USD Million)

Table 7 North America generics market, by type , 2014 - 2025 (USD Million)

Table 8 U.S. pneumonia therapeutics market, by product, 2014 - 2025 (USD Million)

Table 9 U.S. drugs market, by type, 2014 - 2025 (USD Million)

Table 10 U.S. branded drugs market, by type, 2014 - 2025 (USD Million)

Table 11 U.S. generics market, by type , 2014 - 2025 (USD Million)

Table 12 Canada pneumonia therapeutics market, by product, 2014 - 2025 (USD Million)

Table 13 Canada drugs market, by type, 2014 - 2025 (USD Million)

Table 14 Canada branded drugs market, by type, 2014 - 2025 (USD Million)

Table 15 Canada generics market, by type , 2014 - 2025 (USD Million)

Table 16 Europe pneumonia therapeutics market, by product, 2014 - 2025 (USD Million)

Table 17 Europe drugs market, by type, 2014 - 2025 (USD Million)

Table 18 Europe branded drugs market, by type, 2014 - 2025 (USD Million)

Table 19 Europe generics market, by type , 2014 - 2025 (USD Million)

Table 20 Germany pneumonia therapeutics market, by product, 2014 - 2025 (USD Million)

Table 21 Germany drugs market, by type, 2014 - 2025 (USD Million)

Table 22 Germany branded drugs market, by type, 2014 - 2025 (USD Million)

Table 23 Germany generics market, by type , 2014 - 2025 (USD Million)

Table 24 UK pneumonia therapeutics market, by product, 2014 - 2025 (USD Million)

Table 25 UK drugs market, by type, 2014 - 2025 (USD Million)

Table 26 UK branded drugs market, by type, 2014 - 2025 (USD Million)

Table 27 UK generics market, by type , 2014 - 2025 (USD Million)

Table 28 Asia Pacific pneumonia therapeutics market, by product, 2014 - 2025 (USD Million)

Table 29 Asia Pacific drugs market, by type, 2014 - 2025 (USD Million)

Table 30 Asia Pacific branded drugs market, by type, 2014 - 2025 (USD Million)

Table 31 Asia Pacific generics market, by type , 2014 - 2025 (USD Million)

- Table 32 Japan pneumonia therapeutics market, by product, 2014 - 2025 (USD Million)
- Table 33 Japan drugs market, by type, 2014 - 2025 (USD Million)
- Table 34 Japan branded drugs market, by type, 2014 - 2025 (USD Million)
- Table 35 Japan generics market, by type , 2014 - 2025 (USD Million)
- Table 36 China pneumonia therapeutics market, by product, 2014 - 2025 (USD Million)
- Table 37 China drugs market, by type, 2014 - 2025 (USD Million)
- Table 38 China branded drugs market, by type, 2014 - 2025 (USD Million)
- Table 39 China generics market, by type , 2014 - 2025 (USD Million)
- Table 40 India pneumonia therapeutics market, by product, 2014 - 2025 (USD Million)
- Table 41 India drugs market, by type, 2014 - 2025 (USD Million)
- Table 42 India branded drugs market, by type, 2014 - 2025 (USD Million)
- Table 43 India generics market, by type , 2014 - 2025 (USD Million)
- Table 44 Latin America pneumonia therapeutics market, by product, 2014 - 2025 (USD Million)
- Table 45 Latin America drugs market, by type, 2014 - 2025 (USD Million)
- Table 46 Latin America branded drugs market, by type, 2014 - 2025 (USD Million)
- Table 47 Latin America generics market, by type , 2014 - 2025 (USD Million)
- Table 48 Brazil pneumonia therapeutics market, by product, 2014 - 2025 (USD Million)
- Table 49 Brazil drugs market, by type, 2014 - 2025 (USD Million)
- Table 50 Brazil branded drugs market, by type, 2014 - 2025 (USD Million)
- Table 51 Brazil generics market, by type , 2014 - 2025 (USD Million)
- Table 52 Mexico pneumonia therapeutics market, by product, 2014 - 2025 (USD Million)
- Table 53 Mexico drugs market, by type, 2014 - 2025 (USD Million)
- Table 54 Mexico branded drugs market, by type, 2014 - 2025 (USD Million)
- Table 55 Mexico generics market, by type , 2014 - 2025 (USD Million)
- Table 56 MEA pneumonia therapeutics market, by product, 2014 - 2025 (USD Million)
- Table 57 MEA drugs market, by type, 2014 - 2025 (USD Million)
- Table 58 MEA branded drugs market, by type, 2014 - 2025 (USD Million)
- Table 59 MEA generics market, by type , 2014 - 2025 (USD Million)
- Table 60 South Africa pneumonia therapeutics market, by product, 2014 - 2025 (USD Million)
- Table 61 South Africa drugs market, by type, 2014 - 2025 (USD Million)
- Table 62 South Africa branded drugs market, by type, 2014 - 2025 (USD Million)
- Table 63 South Africa generics market, by type , 2014 - 2025 (USD Million)

## LIST OF TABLES

Figure 1 Market summary (USD Million)

Figure 2 Market trends & outlook



- Figure 3 Market segmentation & scope
- Figure 4 Market driver relevance analysis (Current & future impact)
- Figure 5 Market restraint relevance analysis (Current & future impact)
- Figure 6 Penetration & growth prospect mapping
- Figure 7 SWOT Analysis, By Factor (Political & legal, economic and technological)
- Figure 8 Porter's Five Forces Analysis
- Figure 9 Company Market Share, 2016
- Figure 10 Pneumonia therapeutics market, product outlook: Key takeaways
- Figure 11 Pneumonia therapeutics market: Product movement analysis
- Figure 12 Global drugs market, 2014 - 2025 (USD Million)
- Figure 13 Global branded market, 2014 - 2025 (USD Million)
- Figure 14 Global quinolones market, 2014 - 2025 (USD Million)
- Figure 15 Global aminopenicillins market, 2014 - 2025 (USD Million)
- Figure 16 Global macrolides market, 2014 - 2025 (USD Million)
- Figure 17 Global b-lactamase inhibitors market, 2014 - 2025 (USD Million)
- Figure 18 Global cephalosporins market, 2014 - 2025 (USD Million)
- Figure 19 Global tetracyclines market, 2014 - 2025 (USD Million)
- Figure 20 Global glycopeptides antibiotics market, 2014 - 2025 (USD Million)
- Figure 21 Global carbapenems market, 2014 - 2025 (USD Million)
- Figure 22 Global others market, 2014 - 2025 (USD Million)
- Figure 23 Global generics market, 2014 - 2025 (USD Million)
- Figure 24 Global quinolones market, 2014 - 2025 (USD Million)
- Figure 25 Global macrolides market, 2014 - 2025 (USD Million)
- Figure 26 Global others market, 2014 - 2025 (USD Million)
- Figure 27 Regional market place: Key takeaways
- Figure 28 Regional outlook, 2016 & 2025
- Figure 29 Participant categorization

## I would like to order

Product name: Pneumonia Therapeutics Market Analysis By Product (Drugs, Branded, Quinolones, Aminopenicillins, Macrolides, B-lactamase Inhibitors, Cephalosporins, Tetracyclines, Glycopeptides, Generics, Vaccines, Oxygen Therapy) And Segment Forecasts, 2014 - 2025

Product link: <https://marketpublishers.com/r/P91FB104918EN.html>

Price: US\$ 5,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/P91FB104918EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below  
and fax the completed form to +44 20 7900 3970